



## Viamet to Participate in Antifungal Panel Discussion at the 2017 BIO International Convention

RESEARCH TRIANGLE PARK, N.C., June 14, 2017 – [Viamet Pharmaceuticals, Inc.](http://www.viamet.com) today announced that Robert Schotzinger, M.D., Ph.D., President and CEO of Viamet, will be participating in a panel discussion on emerging issues and unmet needs in antifungal development at the 2017 BIO International Convention, taking place on June 19-22 at the San Diego Convention Center in San Diego, CA. The interactive panel will focus on the growing global public health epidemic caused by pathogenic fungi and highlight the urgent need and opportunities for new antifungal therapies. The session titled, “**Antifungus Among Us: Recognizing Vulnerability and Opportunity with the Next-Generation of Antifungals**,” will take place on June 20 at 4:15pm PT and will include experts and representatives from all aspects of these issues including media, regulatory bodies and biotechnology companies.

“While combating drug resistance is the focus of antiviral and antibiotic development, an additional issue in addressing fungal infections is that mortality rates for many invasive fungal infections are still exceedingly high. There continues to be no clear “holy grail” therapy for serious systemic fungal infections as current therapies continue to suffer from suboptimal efficacy, safety, antifungal spectrum and dosing options,” said Dr. Schotzinger. “Some of these infections, such as cryptococcal meningitis, are devastating, especially in the developing world. I’m honored to be included in a panel with multiple experts in the field, and I look forward to discussing the need for innovation in research and development, and the challenges of delivering new and improved therapies to address these significant unmet medical needs both in the U.S. and around the world.”

**Session Name:** Antifungus Among Us: Recognizing Vulnerability and Opportunity with the Next-Generation of Antifungals

**Session ID:** 22252

**Date/Time:** June 20, 2017, 4:15 PM – 5:15PM PT

**Location:** San Diego Convention Center, Room 9

**Moderator:** Luke Timmerman, Founder and Editor, The Timmerman Report

**Panelists:** Tom Chiller, M.D., M.P.H., Associate Director for Epidemiologic Science, Division of Foodborne, Waterborne, and Environmental Diseases, NCEZID, Center for Disease Control & Prevention (CDC)  
Robert Schotzinger, M.D., Ph.D., President and CEO, Viamet Pharmaceuticals  
Marco Taglietti, M.D., President and CEO, SCYNEXIS  
Tim Cooke, Ph.D., CEO, Novadigm Therapeutics  
Jeff Stein, Ph.D., President and CEO, Cidara Therapeutics

### **About Viamet ([www.viamet.com](http://www.viamet.com))**

Viamet discovers and develops breakthrough therapies based on our leadership in metalloenzyme chemistry and biology. Our clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. We also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. Focusing on the needs of patients and clinicians, we design our drug candidates to achieve superior efficacy and safety profiles compared to currently marketed drugs.



*This press release includes forward-looking statements. Actual results may vary materially from these statements. There are many important risks affecting Viamet's business, including that clinical trials may not be commenced, or if commenced, may not be successful, regulatory approvals may not be obtained and approved products, if any, may not achieve commercial success. The Viamet group of companies includes Viamet Pharmaceuticals Holdings, LLC and its operating subsidiaries, Viamet Pharmaceuticals, Inc., VPS-2, Inc., VPS-3, Inc. and Viamet Pharmaceuticals (Bermuda), Ltd. The Viamet group of companies are based in the Research Triangle Park region of North Carolina, USA and Hamilton, Bermuda.*

###

**Media Contact:**

Stefanie Tuck

MacDougall Biomedical Communications

Main: +1 781 235 3060

[stuck@macbiocom.com](mailto:stuck@macbiocom.com)